Gland Pharma announced the approval of a grant under its Employee Stock Option Scheme 2025 (ESOP 2025). The ESOP Compensation Committee granted a total of 1,626 options to one employee on March 03, 2026. The grant details include exercise prices of INR 897.40 for the majority of the options and INR 1/- (face value) for the remainder. The vesting schedule is set over a three-year period concluding in March 2029.
Approval of New Stock Option Grant
Gland Pharma Limited has formally disclosed that its ESOP Compensation Committee, in a meeting held on March 03, 2026, approved the issuance of Employee Stock Options (Grant I) under the Gland Pharma Employee Stock Option Scheme, 2025 (“ESOP 2025”). This action follows previous intimations made on May 22, 2025, and July 03, 2025.
Key Grant Details
The total number of options granted in this tranche is 1,626 (One Thousand Six Hundred and Twenty Six only), allocated to 1 (One) employee of the Company.
Exercise Price Calculation
The pricing for the grant is split into two parts based on the SEBI regulations:
- 1,073 options have an Exercise Price of INR 897.40. This price represents 50% of the closing price of the Equity Share on the NSE as of the grant date, March 03, 2026 (using the closing price of the preceding day, March 02, 2026, as March 03 was a holiday).
- 553 options have an Exercise Price of INR 1/- (Rupee One only), which is the face value of the Equity Share.
Vesting Schedule
The options will vest progressively over three years from the vesting start date of March 03, 2026, according to the following schedule:
- 34% of the total options will vest upon completion of the first year (by March 03, 2027).
- 33% of the total options will vest upon completion of the second year (by March 03, 2028).
- 33% of the total options will vest upon completion of the third year (by March 03, 2029).
Exercise Window
Once vested, the options must be exercised within a maximum period of two years from the respective vesting date.
Administrative Oversight
The administration and governance of the ESOP 2025 scheme, including the terms of this grant, fall under the purview of the ESOP Compensation Committee of the Board of Directors of the Company. All other required details pertaining to options exercised, lapses, or variations of terms are noted as Not Applicable for this specific grant event.
Source: BSE
